BARICITINIB Trademark

Trademark Overview

On Wednesday, October 7, 2020, a trademark application was filed for BARICITINIB with the United States Patent and Trademark Office. The USPTO has given the BARICITINIB trademark a serial number of 90240025. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, April 3, 2023. This trademark is owned by Eli Lilly and Company. The BARICITINIB trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations comprised of baricitinib for the treatment of coronavirus and infectious diseases
baricitinib

General Information

Serial Number90240025
Word MarkBARICITINIB
Filing DateWednesday, October 7, 2020
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, April 3, 2023
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing3000 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s)
Published for Opposition DateTuesday, September 7, 2021

Trademark Statements

Description of MarkThe mark consists of the stylized word "Baricitinib" with the first four letters "Bari" bolded in red and the rest of the letters in black and two red curved lines, bands or streaks, one curving down and one curving up intersecting over the letter "b"
Goods and Services Pharmaceutical preparations comprised of baricitinib for the treatment of coronavirus and infectious diseases
Indication of Colors claimedThe color(s) black and red is/are claimed as a feature of the mark.
Disclaimer with Predetermined Text"BARICITINIB"

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, July 30, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameEli Lilly and Company
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressIndianapolis, IN 46285
Party NameEli Lilly and Company
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressIndianapolis, IN 46285

Trademark Events

Event DateEvent Description
Monday, April 3, 2023ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, April 3, 2023ABANDONMENT - NO USE STATEMENT FILED
Thursday, August 11, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, August 9, 2022SOU EXTENSION 1 GRANTED
Tuesday, August 9, 2022SOU EXTENSION 1 FILED
Tuesday, August 9, 2022TEAS EXTENSION RECEIVED
Tuesday, March 1, 2022NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Sunday, January 16, 2022EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
Tuesday, October 5, 2021EXTENSION OF TIME TO OPPOSE RECEIVED
Tuesday, September 7, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, September 7, 2021PUBLISHED FOR OPPOSITION
Wednesday, August 18, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Friday, July 30, 2021APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, July 27, 2021EXAMINER'S AMENDMENT ENTERED
Tuesday, July 27, 2021NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Tuesday, July 27, 2021EXAMINERS AMENDMENT E-MAILED
Tuesday, July 27, 2021EXAMINERS AMENDMENT -WRITTEN
Monday, July 26, 2021PREVIOUS ALLOWANCE COUNT WITHDRAWN
Tuesday, July 6, 2021WITHDRAWN FROM PUB - OG REVIEW QUERY
Tuesday, June 22, 2021LETTER OF PROTEST EVIDENCE REVIEWED-NO FURTHER ACTION TAKEN
Tuesday, June 22, 2021LETTER OF PROTEST EVIDENCE FORWARDED
Wednesday, March 31, 2021APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, March 26, 2021EXAMINER'S AMENDMENT ENTERED
Friday, March 26, 2021NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Friday, March 26, 2021EXAMINERS AMENDMENT E-MAILED
Friday, March 26, 2021EXAMINERS AMENDMENT -WRITTEN
Wednesday, March 24, 2021ASSIGNED TO EXAMINER
Tuesday, March 16, 2021ASSIGNED TO EXAMINER
Saturday, March 6, 2021ASSIGNED TO EXAMINER
Saturday, November 21, 2020NOTICE OF DESIGN SEARCH CODE E-MAILED
Friday, November 20, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Saturday, October 10, 2020NEW APPLICATION ENTERED

Related Keywords

baricitinib coronavirus infectious diseases treatment preparations comprised pharmaceutical